EGFRt/​19-28z/​IL-12 CAR T / Roswell Park Comprehensive Cancer Center - LARVOL DELTA

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Roswell Park Cancer Institute | N=54 ➔ 1 | Trial completion date: Jun 2029 ➔ Jan 2025 | Suspended ➔ Terminated | Trial primary completion date: Jun 2027 ➔ Jan 2025; Manufacturing issues

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL12A

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=54 | Suspended | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Suspended

Trial suspension • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL12A

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Roswell Park Cancer Institute | N=36 ➔ 54

CAR T-Cell Therapy • Enrollment change • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL12A

Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies (Roswell Park Comprehensive Cancer Center) - "A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor cells express the CD19 protein, an emerging target in clinical cancer research....The study...expects to recruit 36 patients ages 18 and older who have the following hematologic malignancies: Recurrent or refractory chronic lymphocytic leukemia; Recurrent or refractory chronic diffuse large B-cell lymphoma; Recurrent or refractory follicular lymphoma; Recurrent or refractory high-grade B-cell lymphoma; Recurrent or refractory mantle cell lymphoma."

Trial status • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Roswell Park Cancer Institute | Initiation date: Jun 2024 ➔ Sep 2024

CAR T-Cell Therapy • Trial initiation date • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL12A

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL12A

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute

CAR T-Cell Therapy • New P1 trial • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL12A